1. Scrip
  2. >>Therapy Areas
  3. >>Immunological

Phase III studies for new uses of Celgene's Revlimid in multiple myeloma meet endpoints

 
• By Malini Guha

Two recent Phase III trials of Celgene's Revlimid (lenalidomide) have examined the potential for maintenance use of the drug in previously treated patients, while others have examined its use in newly diagnosed multiple myeloma (MM) patients, possibly paving the way for new uses for the drug.

Two recent Phase III trials of Celgene's Revlimid (lenalidomide) have examined the potential for maintenance use of the drug in previously treated patients, while others have examined its use in newly diagnosed multiple myeloma (MM) patients, possibly paving the way for new uses for the drug.

Celgene told Scrip that while the independently-sponsored trials testing maintenance Revlimid met their primary progression-free survival (PFS) endpoints – such as the most recently announced Phase III trial conducted by...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

Degron Eyes Deals For Novel Molecular Glue Degrader Assets

 
• By Dexter Jie Yan

Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.

Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race

 
• By Jessica Merrill

Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

BREAKING NEWS: Sanofi Bets $9.5bn To Bag Blueprint

 
• By Kevin Grogan

Buy boosts the French major's immunology pipeline.

More from Therapeutic Category

ASCO: J&J Banks On T-Cell Engager’s Safety In Prostate Cancer

 
• By Andrew McConaghie

The company highlighted the KLK2-targeting agent’s safety at ASCO but it may have to rely on combinations to make pasritamig competitive.

ASCO: Regeneron Looks To Become Bigger Immuno-Oncology Player

 
• By Alaric DeArment

The drugmaker presented oral abstracts at the meeting for Libtayo in adjuvant cutaneous squamous-cell carcinoma and linvoseltamab in multiple myeloma.

ASCO: Lupin Presents Early Data On PRMT5 Inhibitor

 
• By Vibha Ravi

ASCO sees the debut of Lupin’s PRMT5 inhibitor candidate LRNP7457, currently in Phase I studies in India. While no drug with this mechanism of action has been approved anywhere so far, several candidates are in clinical trials.